Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A

Amy Hanna, Alex Lam, Steffi Tham, Angela dulhunty, Nicole BEARD

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The use of anthracycline chemotherapeutic drugs is restricted owing to potentially fatal cardiotoxic side effects. It has been hypothesized that anthracycline metabolites have a primary role in this cardiac dysfunction; however, information on the molecular interactions of these compounds in the heart is scarce. Here we provide novel evidence that doxorubicin and its metabolite, doxorubicinol, bind to the cardiac ryanodine receptor (RyR2) and to the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2A) and deleteriously alter their activity. Both drugs (0.01 μM–2.5 μM) activated single RyR2 channels, and this was reversed by drug washout. Both drugs caused a secondary inhibition of RyR2 activity that was not reversed by drug washout. Preincubation with the reducing agent dithiothreitol (DTT, 1 mM) prevented drug-induced inhibition of channel activity. Doxorubicin and doxorubicinol reduced the abundance of thiol groups on RyR2, further indicating that oxidation reactions may be involved in the actions of the compounds. Ca2+ uptake into sarcoplasmic reticulum vesicles by SERCA2A was inhibited by doxorubicinol, but not doxorubicin. Unexpectedly, in the presence of DTT, doxorubicinol enhanced the rate of Ca2+ uptake by SERCA2A. Together the evidence provided here shows that doxorubicin and doxorubicinol interact with RyR2 and SERCA2A in similar ways, but that the metabolite acts with greater efficacy than the parent compound. Both compounds modify RyR2 and SERCA2A activity by binding to the proteins and also act via thiol oxidation to disrupt SR Ca2+ handling. These actions would have severe consequences on cardiomyocyte function and contribute to clinical symptoms of acute anthracycline cardiotoxicity
Original languageEnglish
Pages (from-to)438-449
Number of pages12
JournalMolecular Pharmacology
Volume86
Issue number4
DOIs
Publication statusPublished - Oct 2014
Externally publishedYes

Fingerprint

Sarcoplasmic Reticulum Calcium-Transporting ATPases
Ryanodine Receptor Calcium Release Channel
Doxorubicin
Anthracyclines
Pharmaceutical Preparations
Sulfhydryl Compounds
Dithiothreitol
Reducing Agents
Sarcoplasmic Reticulum
Cardiac Myocytes
Carrier Proteins
adriamycinol

Cite this

Hanna, Amy ; Lam, Alex ; Tham, Steffi ; dulhunty, Angela ; BEARD, Nicole. / Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A. In: Molecular Pharmacology. 2014 ; Vol. 86, No. 4. pp. 438-449.
@article{a18551821a264705b118aa9c5c2726f9,
title = "Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A",
abstract = "The use of anthracycline chemotherapeutic drugs is restricted owing to potentially fatal cardiotoxic side effects. It has been hypothesized that anthracycline metabolites have a primary role in this cardiac dysfunction; however, information on the molecular interactions of these compounds in the heart is scarce. Here we provide novel evidence that doxorubicin and its metabolite, doxorubicinol, bind to the cardiac ryanodine receptor (RyR2) and to the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2A) and deleteriously alter their activity. Both drugs (0.01 μM–2.5 μM) activated single RyR2 channels, and this was reversed by drug washout. Both drugs caused a secondary inhibition of RyR2 activity that was not reversed by drug washout. Preincubation with the reducing agent dithiothreitol (DTT, 1 mM) prevented drug-induced inhibition of channel activity. Doxorubicin and doxorubicinol reduced the abundance of thiol groups on RyR2, further indicating that oxidation reactions may be involved in the actions of the compounds. Ca2+ uptake into sarcoplasmic reticulum vesicles by SERCA2A was inhibited by doxorubicinol, but not doxorubicin. Unexpectedly, in the presence of DTT, doxorubicinol enhanced the rate of Ca2+ uptake by SERCA2A. Together the evidence provided here shows that doxorubicin and doxorubicinol interact with RyR2 and SERCA2A in similar ways, but that the metabolite acts with greater efficacy than the parent compound. Both compounds modify RyR2 and SERCA2A activity by binding to the proteins and also act via thiol oxidation to disrupt SR Ca2+ handling. These actions would have severe consequences on cardiomyocyte function and contribute to clinical symptoms of acute anthracycline cardiotoxicity",
keywords = "Doxorubicin, Pharmacology, Cardiac",
author = "Amy Hanna and Alex Lam and Steffi Tham and Angela dulhunty and Nicole BEARD",
note = "Copyright {\circledC} 2014 by The American Society for Pharmacology and Experimental Therapeutics.",
year = "2014",
month = "10",
doi = "10.1124/mol.114.093849",
language = "English",
volume = "86",
pages = "438--449",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A. / Hanna, Amy; Lam, Alex; Tham, Steffi; dulhunty, Angela; BEARD, Nicole.

In: Molecular Pharmacology, Vol. 86, No. 4, 10.2014, p. 438-449.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A

AU - Hanna, Amy

AU - Lam, Alex

AU - Tham, Steffi

AU - dulhunty, Angela

AU - BEARD, Nicole

N1 - Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

PY - 2014/10

Y1 - 2014/10

N2 - The use of anthracycline chemotherapeutic drugs is restricted owing to potentially fatal cardiotoxic side effects. It has been hypothesized that anthracycline metabolites have a primary role in this cardiac dysfunction; however, information on the molecular interactions of these compounds in the heart is scarce. Here we provide novel evidence that doxorubicin and its metabolite, doxorubicinol, bind to the cardiac ryanodine receptor (RyR2) and to the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2A) and deleteriously alter their activity. Both drugs (0.01 μM–2.5 μM) activated single RyR2 channels, and this was reversed by drug washout. Both drugs caused a secondary inhibition of RyR2 activity that was not reversed by drug washout. Preincubation with the reducing agent dithiothreitol (DTT, 1 mM) prevented drug-induced inhibition of channel activity. Doxorubicin and doxorubicinol reduced the abundance of thiol groups on RyR2, further indicating that oxidation reactions may be involved in the actions of the compounds. Ca2+ uptake into sarcoplasmic reticulum vesicles by SERCA2A was inhibited by doxorubicinol, but not doxorubicin. Unexpectedly, in the presence of DTT, doxorubicinol enhanced the rate of Ca2+ uptake by SERCA2A. Together the evidence provided here shows that doxorubicin and doxorubicinol interact with RyR2 and SERCA2A in similar ways, but that the metabolite acts with greater efficacy than the parent compound. Both compounds modify RyR2 and SERCA2A activity by binding to the proteins and also act via thiol oxidation to disrupt SR Ca2+ handling. These actions would have severe consequences on cardiomyocyte function and contribute to clinical symptoms of acute anthracycline cardiotoxicity

AB - The use of anthracycline chemotherapeutic drugs is restricted owing to potentially fatal cardiotoxic side effects. It has been hypothesized that anthracycline metabolites have a primary role in this cardiac dysfunction; however, information on the molecular interactions of these compounds in the heart is scarce. Here we provide novel evidence that doxorubicin and its metabolite, doxorubicinol, bind to the cardiac ryanodine receptor (RyR2) and to the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2A) and deleteriously alter their activity. Both drugs (0.01 μM–2.5 μM) activated single RyR2 channels, and this was reversed by drug washout. Both drugs caused a secondary inhibition of RyR2 activity that was not reversed by drug washout. Preincubation with the reducing agent dithiothreitol (DTT, 1 mM) prevented drug-induced inhibition of channel activity. Doxorubicin and doxorubicinol reduced the abundance of thiol groups on RyR2, further indicating that oxidation reactions may be involved in the actions of the compounds. Ca2+ uptake into sarcoplasmic reticulum vesicles by SERCA2A was inhibited by doxorubicinol, but not doxorubicin. Unexpectedly, in the presence of DTT, doxorubicinol enhanced the rate of Ca2+ uptake by SERCA2A. Together the evidence provided here shows that doxorubicin and doxorubicinol interact with RyR2 and SERCA2A in similar ways, but that the metabolite acts with greater efficacy than the parent compound. Both compounds modify RyR2 and SERCA2A activity by binding to the proteins and also act via thiol oxidation to disrupt SR Ca2+ handling. These actions would have severe consequences on cardiomyocyte function and contribute to clinical symptoms of acute anthracycline cardiotoxicity

KW - Doxorubicin

KW - Pharmacology

KW - Cardiac

UR - http://www.scopus.com/inward/record.url?scp=84907918245&partnerID=8YFLogxK

U2 - 10.1124/mol.114.093849

DO - 10.1124/mol.114.093849

M3 - Article

VL - 86

SP - 438

EP - 449

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -